阿仑单抗诱导治疗抵抗性纯红细胞再生障碍完全缓解。
Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
作者信息
Au Wing-Yan, Lam Clarence C K, Chim Chor-Sang, Pang Annie W K, Kwong Yok-Lam
机构信息
University Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
出版信息
Leuk Res. 2005 Oct;29(10):1213-5. doi: 10.1016/j.leukres.2005.02.018. Epub 2005 Apr 25.
Two patients with pure red cell aplasia (PRCA) refractory to anti-thymocyte globulin, prednisolone, cyclophosphamide, fludarabine, mitoxantrone, dexamethasone and cyclosporine, were treated with alemtuzumab (anti-CD52 antibody). Case 1, a 35-year-old man with idiopathic PRCA, remitted completely with 130 mg of alemtuzumab. Case 2, a 42-year-old man with PRCA due to T-cell large granular lymphocyte (T-LGL) leukaemia, achieved complete remission of the PRCA with 490 mg of alemtuzumab, although the T-LGL leukaemia responded only transiently. There were no significant side effects, and normalization of erythropoiesis was durable. Alemtuzumab is active in PRCA that is idiopathic or secondary to T-cell lymphoproliferative diseases.
两名患有纯红细胞再生障碍性贫血（PRCA）的患者，对抗胸腺细胞球蛋白、泼尼松龙、环磷酰胺、氟达拉滨、米托蒽醌、地塞米松和环孢素治疗无效，接受了阿仑单抗（抗CD52抗体）治疗。病例1是一名35岁患有特发性PRCA的男性，使用130mg阿仑单抗后完全缓解。病例2是一名42岁因T细胞大颗粒淋巴细胞（T-LGL）白血病导致PRCA的男性，使用490mg阿仑单抗后PRCA完全缓解，尽管T-LGL白血病仅短暂缓解。没有明显的副作用，红细胞生成正常化持续存在。阿仑单抗对特发性或继发于T细胞淋巴增殖性疾病的PRCA有效。
Zotero 插件